ANGIODYNAMICS INC (ANGO) FY2026 10-K Annual Report
ANGIODYNAMICS INC (ANGO) 10-K annual report for fiscal year 2026, filed with SEC EDGAR on Jul 14, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ANGIODYNAMICS INC FY2026 10-K Analysis
Business Overview
- • Core business model: design, manufacture, and sale of innovative medical devices for cardiovascular disease and cancer treatment
- • New product emphasis: expanded FDA clearance for NanoKnife System prostate tissue ablation in Dec 2024 and MDR CE mark in Feb 2026 for multiple tumor ablations
- • Strategic shift: divestiture of dialysis, BioSentry (June 2023), and PICC/Midline businesses (Feb 2024); discontinuation of RadioFrequency Ablation and Syntrax lines
- • Quantitative metric: workforce reduced to approximately 632 full-time employees as of May 31, 2026
- • Noteworthy fact: ongoing regulatory challenges delaying FDA clearances amid increased testing requirements and expanded MDR compliance through 2027-2028
Management Discussion & Analysis
- • Revenue $320.2M, up 9.5% YoY ($292.5M in FY 2025); Med Tech grew 18.4% ($150.0M) strongest, Med Device up 2.6% ($170.2M)
- • Gross margin 54.6% vs 53.9% YoY; Med Tech margin 63.6% vs 62.0%, Med Device margin declined 46.7% vs 47.7%
- • Net loss increased to $36.7M from $34.0M; loss per share widened to $0.88 from $0.83
- • Operating cash flow positive $3.1M vs negative $10.1M prior year; capex $2.6M plus $3.4M on unit placements; $1.7M stock buybacks in FY 2025, none in FY 2026
- • Management pursuing restructuring to save $15M annually by FY 2027; share repurchase authorization $15M with $13.3M remaining; key risks include inflation, tariffs, supply chain disruptions
Risk Factors
- • Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act
- • Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs
- • Supply chain vulnerability: Transition of manufacturing to third-party sites in U.S., Costa Rica, Latvia, Italy, Israel, China by Q1 FY2027 with risk of disruptions and increased costs
- • Competitive risk: Price competition intensified by growing purchasing power of GPOs and IDNs, risking contract losses and reduced profitability
- • Financial risk: CEO transition planned by Nov 2026 poses leadership uncertainty potentially impacting operations and investor confidence
ANGIODYNAMICS INC FY2026 Key Financial MetricsXBRL
Revenue
$320M
▲ +9.5% YoY
Net Income
-$37M
▼ -8.1% YoY
Gross Margin
54.6%
▲ +71bp YoY
Operating Margin
-12.5%
▲ +119bp YoY
Net Margin
-11.5%
▲ +15bp YoY
ROE
-21.5%
▼ -293bp YoY
Total Assets
$267M
▼ -4.6% YoY
EPS (Diluted)
$-0.88
▼ -6.0% YoY
Operating Cash Flow
$3M
▲ +130.5% YoY
Source: XBRL data from ANGIODYNAMICS INC FY2026 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ANGIODYNAMICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.